A Novel Scoring System for MYB RNA In Situ Hybridization Displays High Sensitivity and Specificity for Adenoid Cystic Carcinoma in a Clinical Setting.


Journal

Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010

Informations de publication

Date de publication:
19 Jun 2024
Historique:
received: 05 05 2024
accepted: 21 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

MYB RNA in situ hybridization (ISH) has emerged as a reliable and accessible marker to support adenoid cystic carcinoma (ACC) diagnosis, though still not well studied. Here, we report our results in a validation and prospective cohort to improve MYB RNA ISH diagnostic accuracy. 79 cases (23 retrospective and 56 prospective) underwent MYB RNA ISH testing (44 ACC and 35 non-ACC). MYB RNA ISH results were initially interpreted based on previously established (original) scoring criteria. Weighted "i-scores", percent positive tumor cells, percent tumor cells with large signals (% LS), and staining pattern (abluminal, diffuse, focal non-patterned, or negative) were inputs for logistic regression models. Final model performance characteristics were compared with original scoring criteria and MYB::NFIB FISH results. An abluminal pattern was characteristic and exclusive to ACC. All i-scores, % LS, and percent positive were significantly higher in ACC. Original scoring criteria yielded a 95.5% sensitivity (Sn), 68.6% specificity (Sp), and 83.5% accuracy. MYB::NFIB FISH yielded a 42.9% sensitivity, 100% specificity, and 60% accuracy. Optimizing for performance, simplicity, and minimal collinearity, our final model was defined as: abluminal pattern and/or % LS > 16.5%, which resulted in a 93.2% Sn, 97.1% Sp, and 94.9% accuracy for ACC diagnosis. False negatives included an ACC with striking tubular eosinophilia and a MYBL1::NFIB translocated ACC. One false positive exclusive to the final model was a nasopharyngeal carcinoma with MYB amplification. MYB RNA ISH has a higher Sn than MYB::NFIB FISH while retaining high Sp. Our model provides improvements to specificity compared to original scoring criteria and highlight the importance of abluminal staining pattern and % LS. Nonetheless, alternate fusions remain key false negatives while rare non-ACC with other mechanisms of MYB activation may present as false positives.

Sections du résumé

BACKGROUND BACKGROUND
MYB RNA in situ hybridization (ISH) has emerged as a reliable and accessible marker to support adenoid cystic carcinoma (ACC) diagnosis, though still not well studied. Here, we report our results in a validation and prospective cohort to improve MYB RNA ISH diagnostic accuracy.
METHODS METHODS
79 cases (23 retrospective and 56 prospective) underwent MYB RNA ISH testing (44 ACC and 35 non-ACC). MYB RNA ISH results were initially interpreted based on previously established (original) scoring criteria. Weighted "i-scores", percent positive tumor cells, percent tumor cells with large signals (% LS), and staining pattern (abluminal, diffuse, focal non-patterned, or negative) were inputs for logistic regression models. Final model performance characteristics were compared with original scoring criteria and MYB::NFIB FISH results.
RESULTS RESULTS
An abluminal pattern was characteristic and exclusive to ACC. All i-scores, % LS, and percent positive were significantly higher in ACC. Original scoring criteria yielded a 95.5% sensitivity (Sn), 68.6% specificity (Sp), and 83.5% accuracy. MYB::NFIB FISH yielded a 42.9% sensitivity, 100% specificity, and 60% accuracy. Optimizing for performance, simplicity, and minimal collinearity, our final model was defined as: abluminal pattern and/or % LS > 16.5%, which resulted in a 93.2% Sn, 97.1% Sp, and 94.9% accuracy for ACC diagnosis. False negatives included an ACC with striking tubular eosinophilia and a MYBL1::NFIB translocated ACC. One false positive exclusive to the final model was a nasopharyngeal carcinoma with MYB amplification.
CONCLUSIONS CONCLUSIONS
MYB RNA ISH has a higher Sn than MYB::NFIB FISH while retaining high Sp. Our model provides improvements to specificity compared to original scoring criteria and highlight the importance of abluminal staining pattern and % LS. Nonetheless, alternate fusions remain key false negatives while rare non-ACC with other mechanisms of MYB activation may present as false positives.

Identifiants

pubmed: 38896376
doi: 10.1007/s12105-024-01656-z
pii: 10.1007/s12105-024-01656-z
doi:

Substances chimiques

Proto-Oncogene Proteins c-myb 0
MYB protein, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51

Subventions

Organisme : Clinical and Translational Sciences Institute at the University of Pittsburgh
ID : Grant Number UL1-TR-001857

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Saleh E, Ukwas A (2023) Adenoid cystic carcinoma of salivary glands: a 10-year review and an assessment of the current management, surgery, radiotherapy, and chemotherapy. Int J Otolaryngol 2023:7401458
doi: 10.1155/2023/7401458
Robin C, Laboulbène JA (1853) Memoire sur trois productions morbides non decrites. Compte Rend Soc Biol 5:185–196
Seethala RR et al (2007) Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol 31(11):1683–1694
doi: 10.1097/PAS.0b013e3180dc928c
Seethala RR (2017) Basaloid/blue salivary gland tumors. Mod Pathol 30(s1):S84-s95
doi: 10.1038/modpathol.2016.190
Khan AJ et al (2001) Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96(3):149–158
doi: 10.1002/ijc.1013
Conley J, Dingman DL (1974) Adenoid cystic carcinoma in the head and neck (cylindroma). Arch Otolaryngol 100(2):81–90
doi: 10.1001/archotol.1974.00780040087001
Jones AS et al (1997) Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol Allied Sci 22(5):434–443
doi: 10.1046/j.1365-2273.1997.00041.x
Spiro RH, Huvos AG (1992) Stage means more than grade in adenoid cystic carcinoma. Am J Surg 164(6):623–628
doi: 10.1016/S0002-9610(05)80721-4
Stell PM et al (1985) Adenoid cystic carcinoma: the results of radical surgery. Clin Otolaryngol Allied Sci 10(4):205–208
doi: 10.1111/j.1365-2273.1985.tb00242.x
McDermott J et al (2015) Local therapy for metastatic salivary adenoid cystic carcinoma: a surveillance, epidermiology, and end results and national cancer data base analysis. Int J Radiat Oncol Biol phys 94(4):953
doi: 10.1016/j.ijrobp.2015.12.301
Mino M, Pilch BZ, Faquin WC (2003) Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16(12):1224–1231
doi: 10.1097/01.MP.0000096046.42833.C7
Penner CR, Folpe AL, Budnick SD (2002) C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 15(7):687–691
doi: 10.1097/01.MP.0000018973.17736.F8
Vila L et al (2009) Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 22(10):1296–1302
doi: 10.1038/modpathol.2009.95
Nordkvist A et al (1994) Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands. Genes Chromosomes Cancer 10(2):115–121
doi: 10.1002/gcc.2870100206
Persson M et al (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106(44):18740–18744
doi: 10.1073/pnas.0909114106
Brayer KJ et al (2016) Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov 6(2):176–187
doi: 10.1158/2159-8290.CD-15-0859
Fehr A et al (2011) The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol 224(3):322–327
doi: 10.1002/path.2909
Weinreb I et al (2023) Adenoid cystic carcinoma with striking tubular hypereosinophilia: a unique pattern associated with nonparotid location and both canonical and novel EWSR1::MYB and FUS::MYB Fusions. Am J Surg Pathol 47(4):497–503
doi: 10.1097/PAS.0000000000002023
Gao R et al (2014) A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget 5(24):12528–12542
doi: 10.18632/oncotarget.2985
Mitani Y et al (2010) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16(19):4722–4731
doi: 10.1158/1078-0432.CCR-10-0463
Brill LB 2nd et al (2011) Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 24(9):1169–1176
doi: 10.1038/modpathol.2011.86
Rooney SL, Robinson RA (2017) Immunohistochemical expression of MYB in salivary gland basal cell adenocarcinoma and basal cell adenoma. J Oral Pathol Med 46(9):798–802
doi: 10.1111/jop.12617
Pusztaszeri MP et al (2014) MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens. Cancer Cytopathol 122(4):257–265
doi: 10.1002/cncy.21381
Rooper LM et al (2021) MYB RNA in situ hybridization facilitates sensitive and specific diagnosis of adenoid cystic carcinoma regardless of translocation status. Am J Surg Pathol 45(4):488–497
doi: 10.1097/PAS.0000000000001616
Butcher MR et al (2022) MYB RNA in situ hybridization is a useful diagnostic tool to distinguish breast adenoid cystic carcinoma from other triple-negative breast carcinomas. Am J Surg Pathol 46(7):878–888
doi: 10.1097/PAS.0000000000001913
McClelland RA et al (1990) Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50(12):3545–3550
Wickham H (2016) ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag, New York
doi: 10.1007/978-3-319-24277-4
Robin X et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77
doi: 10.1186/1471-2105-12-77
Kosmidis I et al (2023) Mean and median bias reduction in generalized linear models. Stat Computing 30:43–59
doi: 10.1007/s11222-019-09860-6
Long, J., jtools: Analysis and Presentation of Social Scientific Data. 2022.
Friedman J et al (2010) Regularization paths for generalized linear models viacoordinate descent. J Stat Softw 33:1–22
doi: 10.18637/jss.v033.i01
Tadi S et al (2023) MYB RNA detection by in situ hybridisation has high sensitivity and specificity for the diagnosis of adenoid cystic carcinoma. Pathology 55(4):456–465
doi: 10.1016/j.pathol.2023.01.007
Ueda K et al (2023) The landscape of MYB/MYBL1-and Peri-MYB/MYBL1-associated rearrangements in adenoid cystic carcinoma. Mod Pathol 36(10):100274
doi: 10.1016/j.modpat.2023.100274
Yadav U et al (2023) Diagnosis of adenoid cystic carcinoma with striking tubular hypereosinophilia by MYB and EWSR1 breakapart fluorescence in situ hybridization. Head Neck Pathol 17(4):940–951
doi: 10.1007/s12105-023-01596-0
Ferrarotto R et al (2017) Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 35(3):352–360
doi: 10.1200/JCO.2016.67.5264
Sajed DP et al (2017) Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is associated with worse outcome in adenoid cystic carcinoma. Am J Surg Pathol 41(11):1473–1482
doi: 10.1097/PAS.0000000000000945
Zhou MJ et al (2023) Increased retinoic acid signaling decreases lung metastasis in salivary adenoid cystic carcinoma by inhibiting the noncanonical Notch1 pathway. Exp Mol Med 55(3):597–611
doi: 10.1038/s12276-023-00957-7
Ferrarotto R et al (2022) AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 13(8):678
doi: 10.1038/s41419-022-05133-9
Andersson MK, Åman P, Stenman G (2019) IGF2/IGF1R signaling as a therapeutic target in MYB-positive adenoid cystic carcinomas and other fusion gene-driven tumors. Cells. https://doi.org/10.3390/cells8080913
doi: 10.3390/cells8080913
Persson M et al (2012) Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 51(8):805–817
doi: 10.1002/gcc.21965

Auteurs

Mariel Bedell (M)

Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. bedellml@upmc.edu.

Dale W Lewis (DW)

Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Raja R Seethala (RR)

Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH